Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Hormonal Male Contraceptive Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ENO4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ENO4 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for enzymatic assays and HTS screening. |
View ENO4 Products |
| Gene Delivery | ENO4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View ENO4 Products |
| Benchmark Ab | Anti-ENO4 Recombinant Antibody Recombinant positive control for expression validation, Western Blot, and IHC. |
View ENO4 Products |
| Validator | ENO4 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View ENO4 Products |
| Related Target A | ENO1 Ubiquitous enolase isoform. Critical for off-target selectivity and counter-screening panels. |
View ENO1 Products |
| Related Target B | ENO2 Neuronal enolase isoform. Essential counter-screening target to prevent neurotoxicity. |
View ENO2 Products |
| Related Target C | ENO3 Muscle-specific enolase isoform. Required for off-target safety profiling. |
View ENO3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enolase Family Isoform Cross-Reactivity | Highly purified ENO1, ENO2, and ENO3 homolog proteins available for rigorous counter-screening. |
| High-Throughput Screening (HTS) Consistency | Batch-to-batch consistency with sequence-verified, high-purity (>95%) recombinant enzymes. |
| Lack of Validated Controls | Sequence-verified recombinant antibodies and validated siRNA sets included in the ecosystem. |
| Cellular Functional Validation | High-titer Lentiviruses for stable cell line construction to evaluate intracellular target engagement. |
Live ENO4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for non-hormonal male contraceptives is intensifying, with major players shifting focus from systemic hormonal interventions to highly specific, localized testicular targets. ENO4 (Enolase 4), a testis-specific enolase isoform localized to the sperm flagellum, has emerged as a premier target due to its essential role in sperm glycolysis and motility. As first-generation non-hormonal candidates enter preclinical and early clinical evaluation, the next wave of R&D is targeting highly selective small molecule inhibitors of ENO4 to achieve rapid, reversible contraception without disrupting the endocrine system.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups (e.g., Contraceptive R&D Initiatives) | Non-Hormonal Male Contraception | Selectivity Assay (Need high-purity active ENO4 vs. somatic ENO1/2/3 isoforms) |
| RNAi / Gene Silencing | Preclinical Research Institutes | Target Validation & Functional Genomics | Knockdown Validation (Need validated ENO4 siRNA and Lentiviral delivery) |